JP2016531100A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531100A5 JP2016531100A5 JP2016525831A JP2016525831A JP2016531100A5 JP 2016531100 A5 JP2016531100 A5 JP 2016531100A5 JP 2016525831 A JP2016525831 A JP 2016525831A JP 2016525831 A JP2016525831 A JP 2016525831A JP 2016531100 A5 JP2016531100 A5 JP 2016531100A5
- Authority
- JP
- Japan
- Prior art keywords
- construct
- antigen binding
- bispecific antigen
- polypeptide
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 43
- 102000036639 antigens Human genes 0.000 claims 43
- 108091007433 antigens Proteins 0.000 claims 43
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 210000004027 cell Anatomy 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 229960003008 blinatumomab Drugs 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 230000002101 lytic effect Effects 0.000 claims 2
- 238000000691 measurement method Methods 0.000 claims 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000037914 B-cell disorder Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 101100372806 Caenorhabditis elegans vit-3 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 101000633445 Homo sapiens Structural maintenance of chromosomes protein 2 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 102100029540 Structural maintenance of chromosomes protein 2 Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229940127174 UCHT1 Drugs 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229940050282 inebilizumab-cdon Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000386 microscopy Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845948P | 2013-07-12 | 2013-07-12 | |
| US61/845,948 | 2013-07-12 | ||
| US201461927877P | 2014-01-15 | 2014-01-15 | |
| US61/927,877 | 2014-01-15 | ||
| US201461978719P | 2014-04-11 | 2014-04-11 | |
| US61/978,719 | 2014-04-11 | ||
| PCT/US2014/046436 WO2015006749A2 (en) | 2013-07-12 | 2014-07-11 | Bispecific cd3 and cd19 antigen binding contructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531100A JP2016531100A (ja) | 2016-10-06 |
| JP2016531100A5 true JP2016531100A5 (enExample) | 2017-08-17 |
Family
ID=52280737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525831A Withdrawn JP2016531100A (ja) | 2013-07-12 | 2014-07-11 | 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160355588A1 (enExample) |
| EP (1) | EP3019622A4 (enExample) |
| JP (1) | JP2016531100A (enExample) |
| KR (1) | KR20160029128A (enExample) |
| CN (1) | CN105531374A (enExample) |
| AU (1) | AU2014287011A1 (enExample) |
| BR (1) | BR112016000666A2 (enExample) |
| CA (1) | CA2917886A1 (enExample) |
| MX (1) | MX2016000272A (enExample) |
| RU (1) | RU2016104130A (enExample) |
| WO (1) | WO2015006749A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| JP6101638B2 (ja) | 2011-03-03 | 2017-03-22 | ザイムワークス，インコーポレイテッド | 多価ヘテロマルチマー足場設計及び構築物 |
| WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| CN104822704B (zh) * | 2012-06-14 | 2020-02-14 | 医疗生物科学有限公司 | 针对分化簇3(cd3)的人源化的抗体 |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| BR112015029788B1 (pt) | 2013-05-31 | 2024-01-02 | Zymeworks Inc | HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC |
| NZ715896A (en) * | 2013-07-05 | 2022-02-25 | Genmab As | Humanized or chimeric cd3 antibodies |
| PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| BR112016016114A2 (pt) * | 2014-01-15 | 2018-05-22 | Zymeworks Inc | Construtos de ligação a antígeno cd19 e cd3 bi- específico. |
| KR20230004939A (ko) | 2014-02-07 | 2023-01-06 | 맥마스터 유니버시티 | 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| WO2015181805A1 (en) | 2014-05-28 | 2015-12-03 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
| US9751946B2 (en) | 2014-09-12 | 2017-09-05 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
| PT3221359T (pt) | 2014-11-17 | 2020-06-23 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| CN107660214B (zh) * | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| JP6773679B2 (ja) | 2015-03-30 | 2020-10-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域 |
| LT3611192T (lt) * | 2015-05-13 | 2025-06-25 | Ablynx N.V. | T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| EP3916018A1 (en) * | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| CN107849132B (zh) | 2015-06-16 | 2022-03-08 | 豪夫迈·罗氏有限公司 | 人源化的和亲和力成熟的针对FcRH5的抗体和使用方法 |
| CN108137706A (zh) * | 2015-07-15 | 2018-06-08 | 酵活有限公司 | 药物缀合的双特异性抗原结合构建体 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| WO2017055314A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| SG11201803054UA (en) * | 2015-10-13 | 2018-05-30 | Eureka Therapeutics Inc | Antibody agents specific for human cd19 and uses thereof |
| KR20180077271A (ko) * | 2015-11-03 | 2018-07-06 | 암브룩스, 인코포레이티드 | 항-ｃｄ3-폴레이트 컨쥬게이트 및 이의 용도 |
| EP3192810A1 (en) * | 2016-01-14 | 2017-07-19 | Deutsches Krebsforschungszentrum | Psma binding antibody and uses thereof |
| CN109496217B (zh) * | 2016-05-27 | 2023-10-20 | 阿尔托生物科学有限公司 | 具有cd3结合域的基于多聚体il-15的分子的构造和表征 |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| ES2875959T3 (es) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| JP7247091B2 (ja) * | 2016-12-20 | 2023-03-28 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法 |
| US11535666B2 (en) * | 2016-12-30 | 2022-12-27 | Cytocares (Shanghai) Inc. | Trifunctional molecule and application thereof |
| CN108264561B (zh) * | 2016-12-30 | 2021-09-10 | 惠和生物技术(上海)有限公司 | 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用 |
| WO2018155611A1 (ja) * | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| CN119019564A (zh) * | 2017-08-01 | 2024-11-26 | Ab工作室有限公司 | 双特异性抗体及其用途 |
| WO2019071358A1 (en) | 2017-10-12 | 2019-04-18 | Mcmaster University | Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF |
| CN107903324B (zh) * | 2017-11-15 | 2021-01-29 | 北京绿竹生物技术股份有限公司 | 一种结合人cd19和cd3的双特异性抗体 |
| CN107987169B (zh) * | 2018-01-05 | 2021-10-08 | 阿思科力(苏州)生物科技有限公司 | 一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用 |
| CN118772288A (zh) | 2018-02-08 | 2024-10-15 | 豪夫迈·罗氏有限公司 | 双特异性抗原结合分子和使用方法 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| WO2020088164A1 (zh) * | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| JP7261307B2 (ja) * | 2019-01-28 | 2023-04-19 | ウーシー バイオロジクス アイルランド リミテッド | 新規二重特異性ｃｄ３／ｃｄ２０ポリペプチド複合体 |
| CN113660956B (zh) * | 2019-01-28 | 2024-10-29 | Ab诊疗公司 | 双特异性抗体及其用途 |
| CN109776683B (zh) * | 2019-03-19 | 2020-04-07 | 益科思特(北京)医药科技发展有限公司 | 一种双特异性抗体及其制备方法与应用 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| CN112390882A (zh) * | 2019-08-19 | 2021-02-23 | 杨洋 | 靶向cd3和cd20的双特异性抗体及其应用 |
| KR20220113790A (ko) | 2019-12-13 | 2022-08-16 | 제넨테크, 인크. | 항-ly6g6d 항체 및 사용 방법 |
| IL295413A (en) * | 2020-02-27 | 2022-10-01 | Phanes Therapeutics Inc | Antibodies conjugated with fatty acid molecules and their uses |
| IL297986A (en) | 2020-05-08 | 2023-01-01 | Genmab As | Bispecific antibodies against cd3 and cd20 |
| BR112022025856A2 (pt) | 2020-06-19 | 2023-01-10 | Hoffmann La Roche | Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção |
| JP2023542291A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| EP4210743A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| EP4210742A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| BR112023004321A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um sujeito humano |
| JP2023541858A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| WO2022098638A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| MX2023005130A (es) | 2020-11-04 | 2023-05-25 | Genentech Inc | Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3. |
| CN113735978B (zh) * | 2021-04-22 | 2023-06-30 | 河北森朗生物科技有限公司 | 靶向cd19的嵌合抗原受体、制备方法及其应用 |
| KR20240007171A (ko) | 2021-05-14 | 2024-01-16 | 제넨테크, 인크. | 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법 |
| US12016923B2 (en) | 2021-06-01 | 2024-06-25 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 T cell-antigen couplers and uses thereof |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| PT2519543T (pt) * | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
| EP2525899A1 (en) * | 2010-01-22 | 2012-11-28 | Lonza Walkersville, Inc. | High yield method and apparatus for volume reduction and washing of therapeutic cells using tangential flow filtration |
| AU2011325833C1 (en) * | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| NO2748201T3 (enExample) * | 2011-08-23 | 2018-05-12 | ||
| AU2013289883B2 (en) * | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
-
2014
- 2014-07-11 MX MX2016000272A patent/MX2016000272A/es unknown
- 2014-07-11 JP JP2016525831A patent/JP2016531100A/ja not_active Withdrawn
- 2014-07-11 AU AU2014287011A patent/AU2014287011A1/en not_active Abandoned
- 2014-07-11 EP EP14822418.1A patent/EP3019622A4/en not_active Withdrawn
- 2014-07-11 RU RU2016104130A patent/RU2016104130A/ru not_active Application Discontinuation
- 2014-07-11 US US14/903,184 patent/US20160355588A1/en not_active Abandoned
- 2014-07-11 WO PCT/US2014/046436 patent/WO2015006749A2/en not_active Ceased
- 2014-07-11 CN CN201480044366.7A patent/CN105531374A/zh active Pending
- 2014-07-11 CA CA2917886A patent/CA2917886A1/en not_active Abandoned
- 2014-07-11 BR BR112016000666A patent/BR112016000666A2/pt not_active IP Right Cessation
- 2014-07-11 KR KR1020167003567A patent/KR20160029128A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531100A5 (enExample) | ||
| JP7387780B2 (ja) | 抗ｃｄ３８抗体および使用方法 | |
| RU2016104130A (ru) | Биспецифичные конструкции, связывающие антигены cd3 и cd19 | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| RU2742691C2 (ru) | Cd3-связывающий домен | |
| EP3160994B1 (en) | Multispecific antigen binding proteins | |
| JP2021184722A (ja) | Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 | |
| JP2019524693A5 (enExample) | ||
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| BR112021009325A2 (pt) | Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica | |
| JP2016513467A5 (enExample) | ||
| CN107428830A (zh) | 单体fc结构域 | |
| JP2017536829A5 (enExample) | ||
| JP2015519375A5 (enExample) | ||
| JP2015504896A5 (enExample) | ||
| US20200325232A1 (en) | Multispecific antigen binding proteins | |
| CA3220458A1 (en) | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic | |
| CN117616050A (zh) | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 | |
| CA3117864A1 (en) | Novel antagonistic anti tnfr2 antibody molecules | |
| WO2022258691A1 (en) | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a | |
| WO2022258678A1 (en) | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a | |
| CN118974091A (zh) | T细胞结合蛋白 | |
| CN116847863A (zh) | 抗人cd22的单克隆抗体及其用途 | |
| EP4665766A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies |